Search results for "Whooping cough"

showing 10 items of 47 documents

Immunogenicity and reactogenicity of acellular pertussis booster vaccines in children: standard pediatric versus a reduced-antigen content formulatio…

2008

Booster vaccination with a reduced-antigen-content dTpa, pediatric DTPa or adult Td vaccine in DTPa-primed children aged 4-6 years was evaluated. Immunogenicity and CMI was assessed one month and 3.5 years after vaccination. Symptoms were solicited for 15 days post-vaccination. There were no differences between groups in diphtheria or tetanus seroprotection or pertussis vaccine-response rates. Anti-diphtheria and anti-PRN concentrations were higher after DTPa, but groups differences reduced over time. Non-significant trends toward reduced reactogenicity of dTpa were observed. Many factors influence vaccine choice at pre-school age. The dTpa vaccine was as immunogenic and possibly better tol…

MaleWhooping Coughanimal diseasesImmunologyImmunization Secondarycomplex mixturesVaccines AcellularAntigenGermanymedicineHumansGeneral Pharmacology Toxicology and PharmaceuticsChildPertussis VaccineAntigens BacterialReactogenicityBooster (rocketry)TetanusTetanusbusiness.industryDiphtheriaImmunogenicityDiphtheriarespiratory systemmedicine.diseaseAntibodies BacterialVaccinationChild PreschoolImmunologycardiovascular systemFemalebusinessAcellular pertussiscirculatory and respiratory physiologyHuman vaccines
researchProduct

European Sero-Epidemiology Network: standardisation of the assay results for pertussis

2003

A standardisation process was developed in order to compare and harmonize serological results of pertussis toxin (PT) antibody measurements performed by laboratories using different technical procedures for detection. This involved the development of a common panel, of sera by a designed reference centre, the distribution of the panel to each participating laboratory for testing with their routine methods, the comparison of the obtained results to those of the reference centre, and the calculation of standardisation equations by regressing the quantitative results against those of the reference centre. As a cut-off indicative of protection against pertussis has not yet been defined, a parti…

Malemedicine.medical_specialtyAdolescentWhooping CoughEnzyme-Linked Immunosorbent AssayHerd immunitymedicineHumansSero epidemiologyMedical physicsChildHigh titreReference standardsWhooping coughGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryPublic Health Environmental and Occupational HealthReproducibility of ResultsReference Standardsmedicine.diseaseAntibodies BacterialEuropeInfectious DiseasesItalyChild PreschoolCalibrationImmunologyMolecular MedicineFemaleTos ferinabusinessVaccine
researchProduct

PREVALENCE OF PERTUSSIS IgG ANTIBODIES IN CHILDREN IN PALERMO, ITALY

1989

The prevalence of IgG antibodies to Bordetella pertussis in a sample of 615 1-12-year-old unvaccinated children in Palermo was estimated by ELISA. The overall prevalence was 56%; it increased from 24% in one to three-year-old children to 67% in 11-12-year-old children (p less than 0.01). IgG antibody prevalence was not associated with the father's years of schooling (OR 1), nor with the family size (OR 1.3; C.I. 95% = 0.8-2.2). For children aged one the three years, serological results showed that the history of pertussis reported by parents in questionnaires gave high specificity (93.2%) and negative predictive value (85.4%). Our seroepidemiological study evidences a great exposure of chil…

Microbiology (medical)Bordetella pertussisPediatricsmedicine.medical_specialtyWhooping CoughEnzyme-Linked Immunosorbent AssaySensitivity and SpecificitySerologyPredictive Value of TestsSeroepidemiologic StudiesEpidemiologyPrevalencemedicineHumansChildAntibody prevalencebiologybusiness.industryInfantGeneral MedicineElisa assaybiology.organism_classificationPredictive valueInfectious DiseasesItalyEl NiñoChild PreschoolImmunoglobulin Gbiology.proteinAntibodybusiness
researchProduct

Hemolytic uremic syndrome in an infant following Bordetella pertussis infection.

2006

Reported here is the case of a 6-week-old female infant with a severe Bordetella pertussis infection requiring supportive pressure-positive ventilation in the intensive care unit. After being discharged from the intensive care unit, she developed hemolytic anemia, thrombocytopenia and acute renal failure, which suggested a diagnosis of hemolytic uremic syndrome. The clinical outcome was favorable with no renal consequences. This case suggests there may be a direct cause-effect relationship between B. pertussis infection and hemolytic uremic syndrome.

Microbiology (medical)Hemolytic anemiaPediatricsmedicine.medical_specialtyBordetella pertussisWhooping CoughPertussis toxinBordetella pertussislaw.inventionMedical microbiologylawmedicineHumansbiologybusiness.industryInfantGeneral Medicinebiology.organism_classificationmedicine.diseaseIntensive care unitInfectious DiseasesHemolytic-Uremic SyndromeImmunologyParoxysmal coughFemalebusinessKidney disease
researchProduct

Immunogenicity and reactogenicity of HbOC vaccine administered simultaneously with acellular pertussis vaccine (DTaP) into either arms or thighs of i…

1997

To evaluate the reactogenicity and immunogenicity of a Haemophilus influenzae type b conjugate vaccine (HbOC) and of a tricomponent acellular pertussis vaccine (DTaP) when injected simultaneously into either contralateral arms or into contralateral thighs, 110 infants were enrolled to receive three doses of DTaP at 3, 4, and 5 months and two HbOC doses at 3 and 5 months of age. Administration of either of the two vaccines into arms was associated with significantly more local side effects than administration into thighs. There was no difference in geometric mean concentration (GMC) values for any of the four vaccine antigens between subjects who had been vaccinated into arms or thighs. Afte…

Microbiology (medical)MaleConjugate vaccinemedicineHumansWhooping coughBacterial CapsulesHaemophilus VaccinesPertussis VaccineReactogenicityVaccines Conjugatebusiness.industryTetanusDiphtheriaImmunogenicityPolysaccharides BacterialToxoidInfantGeneral Medicinemedicine.diseaseAntibodies BacterialVaccinationInfectious DiseasesImmunologyFemalebusinessInfection
researchProduct

Four and One-Half-Year Follow-up of the Effectiveness of Diphtheria-Tetanus Toxoids-Acellular Pertussis/Haemophilus influenzae Type b and Diphtheria-…

2004

Background: Recently an increase in the number of invasive Haemophilus influenzae type b (Hib) cases was observed in the United Kingdom, which coincided with a temporary change from diphtheria-tetanus toxoids-wild-type pertussis to diphtheria-tetanus toxoids-acellular pertussis (DTaP) Hib vaccines. A study in Germany based on approximately 2 years of follow-up, estimated vaccine effectiveness (VE) of DTaP/Hib and DTaP-inactivated poliovirus/Hib combination vaccines against invasive Hib disease to be high. Objectives: To assess VE of DTaP-containing Hib vaccines against Hib in Germany with the use of extended follow-up of case surveillance and vaccine uptake. Subjects and Methods: Cases with…

Microbiology (medical)Pediatricsmedicine.medical_specialtyHaemophilus InfectionsBooster doseDiphtheria-Tetanus-acellular Pertussis Vaccinesmedicine.disease_causecomplex mixturesHaemophilus influenzaeCohort StudiesGermanymedicineHumansVaccines CombinedWhooping coughHaemophilus VaccinesRetrospective Studiesbusiness.industryTetanusDiphtheriaPoliovirusHaemophilus influenzae type bToxoidInfantbacterial infections and mycosesmedicine.diseaseVirologyPoliovirus VaccinesInfectious DiseasesCase-Control StudiesChild PreschoolPediatrics Perinatology and Child HealthEnterovirusbusinessPediatric Infectious Disease Journal
researchProduct

Haemophilus influenzae type b disease: impact and effectiveness of diphtheria-tetanus toxoids-acellular pertussis (-inactivated poliovirus)/H. influe…

2001

Background. Since 1996 in Germany primary infant immunization against Haemophilus influenzae has been most commonly given in the form of diphtheria-tetanus toxoids-acellular pertussis/H. influenzae type b (DTaP/Hib) or diphtheria-tetanus toxoids-acellular pertussis (-inactivated poliovirus)/H. influenzae type b (DTaP-IPV/Hib) combination vaccines. These combination vaccines elicit lower anti-Hib antibody concentrations than the equivalent Hib conjugate administered as a separate injection, but the clinical relevance of this phenomenon is unknown. Methods and findings. To assess the impact of DTaP/Hib combination vaccines on the incidence of invasive Hib disease in Germany, two independent s…

Microbiology (medical)Pediatricsmedicine.medical_specialtyHaemophilus Infectionsmedicine.disease_causeDiphtheria-Tetanus-acellular Pertussis Vaccinescomplex mixturesHaemophilus influenzaeGermanymedicineHumansVaccines CombinedWhooping coughImmunization ScheduleHaemophilus Vaccinesbusiness.industryTetanusDiphtheriaIncidenceVaccinationToxoidHaemophilus influenzae type bInfantmedicine.diseaseAntibodies BacterialVaccinationPoliovirus Vaccine InactivatedInfectious DiseasesImmunizationChild PreschoolPediatrics Perinatology and Child HealthImmunologybusinessMeningitisSentinel SurveillanceThe Pediatric infectious disease journal
researchProduct

Clinical experience of a tricomponent acellular pertussis vaccine combined with diphtheria and tetanus toxoids for primary vaccination in 22,505 infa…

1996

Abstract OBJECTIVES: To assess the safety and tolerability of 12 lots of SmithKline Beecham Biologicals' diphtheria-tetanus-tricomponent acellular pertussis vaccine (DTaP) in a large cohort of 22,000 vaccinees, with detailed analyses of reactivity, immunogenicity, and immune response to pertussis toxin in subsets. METHODS: In a prospective, double-blind, multicenter trial in Germany, 22,505 healthy infants received three vaccinations of DTaP at age 3, 4, and 5 months. Serious adverse events were followed for 1 month after each vaccination, and neurologic events for 1 year or longer. Serum IgG antibodies were assayed before vaccination and 1 month after vaccination. RESULTS: After 67,000 dos…

Pediatricsmedicine.medical_specialtyFeverFilamentous haemagglutinin adhesinDouble-Blind MethodSeizuresGermanyMedicineHumansProspective StudiesAdverse effectWhooping coughDiphtheria-Tetanus-Pertussis VaccineEpilepsybusiness.industryTetanusDiphtheriaIncidenceInfantSudden infant death syndromemedicine.diseaseVaccinationPediatrics Perinatology and Child HealthImmunologyPertactinbusinessSpasms InfantileSudden Infant DeathThe Journal of pediatrics
researchProduct

Immunogenicity, reactogenicity and safety of a 7-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a DTPa-HBV-IPV/Hib combi…

2006

Abstract Background To evaluate immunogenicity, reactogenicity, and safety of a hexavalent combination vaccine diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio virus- Haemophilus influenzae type b (DTPa-HBV-IPV/Hib) when coadministered with a 7-valent pneumococcal conjugate vaccine (PCV7). Methods Infants received either a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio virus- H. influenzae type b vaccine concomitantly with PCV7 or DTPa-HBV-IPV/Hib alone infants were vaccinated at 2, 3 and 4 months (primary immunization) and 12–15 months of age (booster dose). Local and systemic reactions and adverse events were monitored following each do…

Pediatricsmedicine.medical_specialtyPopulationBooster doseDiphtheria-Tetanus-acellular Pertussis Vaccinescomplex mixturesPneumococcal conjugate vaccinePneumococcal VaccinesmedicineHumansHepatitis B VaccinesVaccines CombinededucationWhooping coughBacterial CapsulesHaemophilus Vaccineseducation.field_of_studyReactogenicityGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryTetanusDiphtheriaPolysaccharides BacterialPublic Health Environmental and Occupational HealthInfantmedicine.diseaseVaccinationPoliovirus Vaccine InactivatedInfectious DiseasesImmunologyAntibody FormationMolecular MedicineImmunizationbusinessmedicine.drugVaccine
researchProduct

International Bordetella pertussis assay standardization and harmonization meeting report. Centers for Disease Control and Prevention, Atlanta, Georg…

2009

An international meeting on Bordetella pertussis assay standardization and harmonization was held at the Centers for Disease Control and Prevention (CDC), Atlanta, GA, 19-20 July 2007. The goal of the meeting was to harmonize the immunoassays used for pertussis diagnostics and vaccine evaluation, as agreed upon by academic and government researchers, regulatory authorities, vaccine manufacturers, and the World Health Organization (WHO). The primary objectives were (1) to provide epidemiologic, laboratory, and statistical background for support of global harmonization; (2) to overview the current status of global epidemiology, pathogenesis and immunology of pertussis; (3) to develop a consen…

Settore MED/07 - Microbiologia E Microbiologia ClinicaBordetella pertussisStandardizationVaccine evaluationU.S.HarmonizationMedical and Health SciencesArticleBordetella pertussisPertussis vaccinesVirologyHumansMedicineCenters for Disease Control and PreventionWhooping coughLicensureGovernmentMedical educationWhooping coughAgricultural and Veterinary SciencesGeneral VeterinaryGeneral Immunology and MicrobiologybiologyClinical Laboratory Techniquesbusiness.industryPublic Health Environmental and Occupational HealthStandardization of serologic assaysBiological Sciencesbiology.organism_classificationmedicine.diseaseUnited StatesAtlantaInfectious DiseasesImmunologyBordetella pertussis Whooping cough Standardization of serologic assays ELISA Pertussis vaccinesMolecular MedicineELISAbusinessVaccine
researchProduct